Show simple item record

dc.contributor.authorCatto, M.en
dc.contributor.authorBerezin, Andrey A.en
dc.contributor.authorLo Re, D.en
dc.contributor.authorLoizou, G.en
dc.contributor.authorDemetriades, Marinaen
dc.contributor.authorDe Stradis, A.en
dc.contributor.authorCampagna, F.en
dc.contributor.authorKoutentis, Panayiotis Andreasen
dc.contributor.authorCarotti, A.en
dc.creatorCatto, M.en
dc.creatorBerezin, Andrey A.en
dc.creatorLo Re, D.en
dc.creatorLoizou, G.en
dc.creatorDemetriades, Marinaen
dc.creatorDe Stradis, A.en
dc.creatorCampagna, F.en
dc.creatorKoutentis, Panayiotis Andreasen
dc.creatorCarotti, A.en
dc.date.accessioned2019-11-21T06:17:16Z
dc.date.available2019-11-21T06:17:16Z
dc.date.issued2012
dc.identifier.urihttp://gnosis.library.ucy.ac.cy/handle/7/55311
dc.description.abstractAlzheimer's disease (AD) onset and progression are associated with the dysregulation of multiple and complex physiological processes and a successful therapeutic approach should therefore address more than one target. Two new chemical entities, the easily accessible heterocyclic scaffolds 1,3-diphenylbenzo[e][1,2,4]triazin-7(1H)-one (benzotriazinone I) and 2-phenyl-6H-[1,2,4]triazino[5,6,1-jk]carbazol-6-one (triazafluoranthenone II), were explored for their multitarget-directed inhibition of beta-amyloid (Aβ) fibrillization and acetyl- (AChE) and/or butyryl- (BChE) cholinesterase, three valuable targets for AD therapy. Introduction of appropriate amine substituents at positions 6 and 5 on scaffold I and II, respectively, allowed the preparation of a series of compounds that were tested as Aβ1-40 aggregation and cholinesterase inhibitors. Potent inhibitors of Aβ self-aggregation were discovered and among them benzotriazinone 7 exhibited an outstanding IC50 equal to 0.37 μM. Compounds bearing a basic amine linked to the heterocyclic scaffold through a linear alkyl chain of varying length also afforded good ChE inhibitors. In particular, benzotriazinone 24 and triazafluoranthenone 38 were endowed with an interesting multiple activity, the former displaying IC50 values of 1.4, 1.5 and 1.9 μM on Aβ aggregation and AChE and BChE inhibition, respectively, and the latter showing IC50 values of 1.4 and an outstanding 0.025 μM in the Aβ aggregation and BChE inhibition, respectively. Benzotriazinone 24 and triazafluoranthenone 29, selected owing to their suitable aqueous solubility and Aβ aggregation inhibition, were submitted to a time course kinetic assay followed with thioflavin T (ThT) spectrofluorimetry, circular dichroism (CD) and transmission electron microscopy (TEM). Experimental data indicated that 24 acted at a low concentration ratio (10 μM 24 vs. 50 μM Aβ), stabilizing the unstructured Aβ peptide and inhibiting fibrillogenesis, and that 29 also acted as fibrillization inhibitor, but likely enhancing and stabilizing the β-sheet arrangement of Aβ to yield protofibrillar species as detected by TEM. © 2012 Elsevier Masson SAS. All rights reserved.en
dc.sourceEuropean journal of medicinal chemistryen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84867830552&doi=10.1016%2fj.ejmech.2012.10.003&partnerID=40&md5=1319e250fe5e06e986bb34541ac9300a
dc.subjectβ-Amyloid aggregation inhibitorsel
dc.subjectarticleen
dc.subjectunclassified drugen
dc.subjectAnimalsen
dc.subjectprotein targetingen
dc.subjectStructure-Activity Relationshipen
dc.subjectdrug synthesisen
dc.subjectdrug designen
dc.subjectaqueous solutionen
dc.subjectconcentration responseen
dc.subjectbeta sheeten
dc.subjectprotein aggregationen
dc.subjectcollagen fibrilen
dc.subjectconformationen
dc.subjectMolecular Structureen
dc.subjectprotein stabilityen
dc.subjectthin layer chromatographyen
dc.subjectDose-Response Relationship, Drugen
dc.subjectstructure activity relationen
dc.subjectIC 50en
dc.subjectPeptide Fragmentsen
dc.subjectbinding siteen
dc.subjectcircular dichroismen
dc.subjectbiological activityen
dc.subjectHorsesen
dc.subjectAlzheimer's diseaseen
dc.subjectamyloid beta proteinen
dc.subjectAmyloid beta-Peptidesen
dc.subjectsubstitution reactionen
dc.subject2 phenyl 5 (4 phenylpiperidin 1 yl) 6h (1,2,4)triazino (5,6,1 jk)carbazol 6 oneen
dc.subject5 (n benzyl n methylamino) 2 phenyl 6h (1,2,4)triazino(5,6,1 jk)carbazol 6 oneen
dc.subject5 [[8 [benzyl(methyl)amino]octyl]amino] 2 phenyl 6h (1,2,4)triazino(5,6,1 jk) carbazol 6 oneen
dc.subject5 [n [3 (dimethylamino)propyl] n methylamino] 2 phenyl 6h (1,2,4)triazino(5,6,1 jk) carbazol 6 oneen
dc.subject6 (2 methylpiperidin 1 yl) 1,3 diphenylbenzo(e)(1,2,4)triazin 7 (1h) oneen
dc.subject6 (3 methylpiperidin 1 yl) 1,3 diphenylbenzo(e)(1,2,4)triazin 7 (1h) oneen
dc.subject6 (3,5 dimethylpiperidin 1 yl) 1,3 diphenylbenzo(e)(1,2,4)triazin 7 (1h) oneen
dc.subject6 (4 benzylpiperazin 1 yl) 1,3 diphenylbenzo(e)(1,2,4)triazin 7 (1h) oneen
dc.subject6 (4 methylpiperidin 1 yl) 1,3 diphenylbenzo(e)(1,2,4)triazin 7 (1h) oneen
dc.subject6 (4 phenylpiperidin 1 yl) 1,3 diphenylbenzo(e)(1,2,4)triazin 7 (1h) oneen
dc.subject6 (azepan 1 yl) 1,3 diphenylbenzo(e)(1,2,4)triazin 7(1h)oneen
dc.subject6 (n benzyl n ethylamino) 1,3 diphenylbenzo(e)(1,2,4)triazin 7(1h)oneen
dc.subject6 (n benzyl n methylamino) 1,3 diphenylbenzo(e)(1,2,4)triazin 7(1h)oneen
dc.subject6 [3,4 dihydroquinolin 1 (2h)yl] 1,3 diphenylbenzo(e)(1,2,4)triazin 7(1h)oneen
dc.subject6 [8 (n benzyl n methylamino)octylamino] 1,3 diphenylbenzo(e)(1,2,4)triazin 7(1h)oneen
dc.subject6 [n [3 (dimethylamino)propyl] n methylamino] 1,3 diphenylbenzo(e)(1,2,4) triazin 7(1h) oneen
dc.subject6 morpholino 1,3 diphenylbenzo(e)(1,2,4)triazin 7 (1h)oneen
dc.subject6 thiomorpholino 1,3 diphenylbenzo(e)(1,2,4)triazin 7 (1h)oneen
dc.subjectacetylcholinesteraseen
dc.subjectBenzotriazinonesen
dc.subjectButyrylcholinesteraseen
dc.subjectcholinesteraseen
dc.subjectcholinesterase inhibitoren
dc.subjectCholinesterase inhibitorsen
dc.subjectcompetitive inhibitionen
dc.subjectElectrophorusen
dc.subjectMultitarget-directed ligandsen
dc.subjectspectrofluorometryen
dc.subjectthioflavineen
dc.subjecttransmission electron microscopyen
dc.subjectTriazafluoranthenonesen
dc.titleDesign, synthesis and biological evaluation of benzo[e][1,2,4]triazin-7(1H) -one and [1,2,4]-triazino[5,6,1-jk]carbazol-6-one derivatives as dual inhibitors of beta-amyloid aggregation and acetyl/butyryl cholinesteraseen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ejmech.2012.10.003
dc.description.volume58
dc.description.startingpage84
dc.description.endingpage97
dc.author.faculty002 Σχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences
dc.author.departmentΤμήμα Χημείας / Department of Chemistry
dc.type.uhtypeArticleen
dc.description.notes<p>Cited By :21</p>en
dc.source.abbreviationEur.J.Med.Chem.en
dc.contributor.orcidKoutentis, Panayiotis Andreas [0000-0002-4652-7567]
dc.gnosis.orcid0000-0002-4652-7567


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record